ReviewVirulence2017
Targeting Candida albicans filamentation for antifungal drug development.
Review in Virulence, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed.
- Miltefosine regulates gene expression related to morphogenesis and zinc metabolism inMicrobiology spectrum · 2026Article
- The unique Efg1 fungal virulence regulon in the catheterized bladder environment.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Inhibitory effect of Acetylshikonin on drug-resistant Candida albicans.Gut pathogens · 2026Article
- Disruption of thePathogens (Basel, Switzerland) · 2026Article
- Adh1-Programmed SNF1 Phosphogradients Decrypt Morphogenesis in Candida albicans: Chemical Interrogation Unveils Hyphal Transition Thresholds.Microbial biotechnology · 2026Article
- The chromatin remodeling factor Arp9 modulates drug-resistance and plays a key role in aflatoxins biosynthesis under mammalian-physiological-temperature in Aspergillus flavus.PLoS pathogens · 2026Article
- Aloe emodin disrupts Candida albicans mitochondrial iron homeostasis against its hyphal development and oral candidiasis.Applied microbiology and biotechnology · 2026Article
- The hidden cost of antibiotics: microbial dysbiosis-induced SCFA imbalance and its underlying mechanisms.Frontiers in immunology · 2026Review
- Mitochondrial anchor protein Num11 is key to pathogenicity ofVirulence · 2025Article
- The Unique Efg1 Fungal Virulence Regulon in the Catheterized Bladder Environment.bioRxiv : the preprint server for biology · 2025Article
- Synergistic antifungal activity of lepidium sativum ZnO nanoparticles and nystatin against resistant candida species.Scientific reports · 2025Article
- A Comprehensive Overview ofJournal of fungi (Basel, Switzerland) · 2025Review
- A brief history of phosphatidylinositol transfer proteins: from the backwaters of cell biology to prime time in lipid signaling.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2025Review
- Chitosan nanoparticles encapsulating farnesol show potent antifungal activity against Candida albicans biofilms.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Inhibitory effect of copper chelators on the budding inAntimicrobial agents and chemotherapy · 2025Article
- Aloin remodels the cell wall of Candida albicans to reduce its hyphal virulence against oral candidiasis.Applied microbiology and biotechnology · 2025Article
- The Cwr1 protein kinase localizes to the plasma membrane and mediates resistance to cell wall stress inmSphere · 2024Article
- Long-chain 4-aminoquinolines inhibit filamentation and increase efficacy of nystatin against Candida albicans infections in vivo.NPJ biofilms and microbiomes · 2024Article
- Unveiling the roles ofVirulence · 2024Article
- Conserved signaling modules regulate filamentous growth in fungi: a model for eukaryotic cell differentiation.Genetics · 2024Review
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Candida albicans remains the main etiological agent of candidiasis, as this otherwise normal commensal of humans is capable of causing active infection in immune- and medically-compromised patients. The high morbidity and mortality rates associated with candidiasis, coupled with the emergence of drug resistance demand the development of novel therapeutic strategies. However, there is a paucity of selective targets that can be exploited in the development of new antifungals. Contrary to conventional antibiotics that kill or curtail growth, specifically targeting virulence mechanisms represents an attractive option for antifungal drug development. In C. albicans, a growing body of research over the last few decades has provided important insights into its virulence factors and their contribution to the pathogenesis of candidiasis. Of these, filamentation is the one that has received the most attention and perhaps shows the most promise as a target for new anti-virulence strategies to combat C. albicans infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.